Other frequent mutations comprise EML4 inversion rearrangement with ALK generating EML4-ALK fusion oncogene that is found in 2–7% of NSCLC cases who are mainly non-smoker adenocarcinoma patients of a median age of 55 years [28,77]. Here, ALK is linked to adenocarcinoma.